All PlansAdministrativeHigh impact
Voluntary nationwide recall: Sodium Bicarb and Atropine (Hospira – December)
UPMC Health Plan·Pharmacy, Critical Care, Emergency Medicine·Pharmacy
Effective date
Dec 21, 2023
We identified it
Aug 7, 2026
Summary
Hospira Inc. is voluntarily recalling specific lots of 4.2% and 8.4% Sodium Bicarbonate Injection, USP, and Atropine Sulfate Injection, USP due to discovered glass particles that pose risk of local irritation, blood vessel blockage, or life-threatening blood clots. Billing teams must ensure affected medications are not dispensed and coordinate with pharmacy and providers to halt usage of recalled lots immediately.
Action Required
Immediately: Pharmacy team must identify and quarantine all Hospira Sodium Bicarbonate Injection (4.2% and 8.4%) and Atropine Sulfate Injection inventory matching recalled lot numbers. Billing team must flag any claims submitted using recalled lots for potential refund processing. Contact Sedgwick Inc. at 1-800-805-3093 (TTY: 711, Monday-Friday 8 a.m.–5 p.m. EST) to confirm lot numbers and obtain return/disposal instructions. Update EMR/billing system with alert to prevent future orders of affected lots. Providers must be notified to discontinue use immediately. Any adverse events or complications from prior administration of affected lots must be reported to FDA and documented in patient records. Failure to quarantine and stop usage could result in patient harm liability and regulatory penalties.